CN118512481B - 墨黑色素在制备治疗慢性溃疡性结肠炎及其伴随抑郁样行为的药物中的用途 - Google Patents
墨黑色素在制备治疗慢性溃疡性结肠炎及其伴随抑郁样行为的药物中的用途 Download PDFInfo
- Publication number
- CN118512481B CN118512481B CN202410496410.3A CN202410496410A CN118512481B CN 118512481 B CN118512481 B CN 118512481B CN 202410496410 A CN202410496410 A CN 202410496410A CN 118512481 B CN118512481 B CN 118512481B
- Authority
- CN
- China
- Prior art keywords
- mspi
- mice
- behavior
- score
- brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010009900 Colitis ulcerative Diseases 0.000 title claims abstract description 35
- 201000006704 Ulcerative Colitis Diseases 0.000 title claims abstract description 35
- 230000001684 chronic effect Effects 0.000 title claims abstract description 23
- 230000007267 depressive like behavior Effects 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims abstract description 19
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 title claims description 24
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 239000002552 dosage form Substances 0.000 claims description 4
- 229940098363 cuttle fish ink Drugs 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- QSLFDILMORXPKP-UHFFFAOYSA-N (3-methylimidazol-3-ium-1-yl)-methylsulfanylphosphinate Chemical compound CSP([O-])(=O)N1C=C[N+](C)=C1 QSLFDILMORXPKP-UHFFFAOYSA-N 0.000 abstract description 65
- 102000055046 tissue-factor-pathway inhibitor 2 Human genes 0.000 abstract description 55
- 108010016054 tissue-factor-pathway inhibitor 2 Proteins 0.000 abstract description 55
- 230000002757 inflammatory effect Effects 0.000 abstract description 18
- 230000036542 oxidative stress Effects 0.000 abstract description 18
- 208000024891 symptom Diseases 0.000 abstract description 11
- 210000005027 intestinal barrier Anatomy 0.000 abstract description 10
- 102100035904 Caspase-1 Human genes 0.000 abstract description 8
- 108090000426 Caspase-1 Proteins 0.000 abstract description 8
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 abstract description 8
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract description 8
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract description 8
- 102100039360 Toll-like receptor 4 Human genes 0.000 abstract description 8
- 230000006399 behavior Effects 0.000 abstract description 8
- 230000007358 intestinal barrier function Effects 0.000 abstract description 8
- 239000000049 pigment Substances 0.000 abstract description 5
- 230000009223 neuronal apoptosis Effects 0.000 abstract description 4
- 230000002490 cerebral effect Effects 0.000 abstract description 3
- 230000004914 glial activation Effects 0.000 abstract description 3
- 230000003962 neuroinflammatory response Effects 0.000 abstract description 3
- 230000019491 signal transduction Effects 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 63
- 210000004027 cell Anatomy 0.000 description 27
- 210000001072 colon Anatomy 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 238000010186 staining Methods 0.000 description 26
- 210000005013 brain tissue Anatomy 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 24
- 210000004556 brain Anatomy 0.000 description 20
- 230000001965 increasing effect Effects 0.000 description 20
- 230000006907 apoptotic process Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 239000002158 endotoxin Substances 0.000 description 15
- 230000000968 intestinal effect Effects 0.000 description 15
- 229920006008 lipopolysaccharide Polymers 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 11
- 239000003642 reactive oxygen metabolite Substances 0.000 description 11
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000002055 immunohistochemical effect Effects 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 8
- 210000001130 astrocyte Anatomy 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 description 7
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 7
- 108010087999 Steryl-Sulfatase Proteins 0.000 description 7
- 102000000591 Tight Junction Proteins Human genes 0.000 description 7
- 108010002321 Tight Junction Proteins Proteins 0.000 description 7
- 238000011532 immunohistochemical staining Methods 0.000 description 7
- 229940118019 malondialdehyde Drugs 0.000 description 7
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 6
- 108090000397 Caspase 3 Proteins 0.000 description 6
- 102100029855 Caspase-3 Human genes 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 244000005709 gut microbiome Species 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 210000003097 mucus Anatomy 0.000 description 6
- 238000012346 open field test Methods 0.000 description 6
- 210000000225 synapse Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 5
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 210000001320 hippocampus Anatomy 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 230000015654 memory Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 4
- 102000000018 Chemokine CCL2 Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 238000012048 forced swim test Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 3
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000736262 Microbiota Species 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 210000001642 activated microglia Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000009266 disease activity Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000000274 microglia Anatomy 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000000513 principal component analysis Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- 230000003956 synaptic plasticity Effects 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 230000003936 working memory Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- 238000010826 Nissl staining Methods 0.000 description 2
- 102000003940 Occludin Human genes 0.000 description 2
- 108090000304 Occludin Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 210000001056 activated astrocyte Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 208000027503 bloody stool Diseases 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 210000004953 colonic tissue Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 230000007277 glial cell activation Effects 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 2
- 230000003870 intestinal permeability Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000006724 microglial activation Effects 0.000 description 2
- 230000002025 microglial effect Effects 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000003959 neuroinflammation Effects 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- SGNZYJXNUURYCH-UHFFFAOYSA-N 5,6-dihydroxyindole Chemical compound C1=C(O)C(O)=CC2=C1NC=C2 SGNZYJXNUURYCH-UHFFFAOYSA-N 0.000 description 1
- YFTGOBNOJKXZJC-UHFFFAOYSA-N 5,6-dihydroxyindole-2-carboxylic acid Chemical compound OC1=C(O)C=C2NC(C(=O)O)=CC2=C1 YFTGOBNOJKXZJC-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101001039702 Escherichia coli (strain K12) Methyl-accepting chemotaxis protein I Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 1
- 108010034143 Inflammasomes Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 101000718227 Mus musculus Adhesion G protein-coupled receptor E1 Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000055102 bcl-2-Associated X Human genes 0.000 description 1
- 108700000707 bcl-2-Associated X Proteins 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000025698 brain inflammatory disease Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 210000001947 dentate gyrus Anatomy 0.000 description 1
- 230000007357 depressive behavior Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000004609 intestinal homeostasis Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000013539 mentalization-based treatment Methods 0.000 description 1
- 230000007150 microbiota gut brain axis Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000001703 neuroimmune Effects 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 210000002267 nissl body Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 210000003538 post-synaptic density Anatomy 0.000 description 1
- 108010092804 postsynaptic density proteins Proteins 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000014786 regulation of synaptic transmission Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000002023 somite Anatomy 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明涉及生物医药技术领域,公开了一种墨黑色素在制备治疗慢性溃疡性结肠炎及其伴随抑郁样行为的药物中的用途。本发明首次发现墨黑色素具备治疗慢性溃疡性结肠炎及其伴随抑郁样行为的功效。MSPI可抑制LPS/TLR4/NLRP3/ASC/Caspase‑1炎症信号通路,减轻氧化应激,恢复肠道屏障,从而改善UC症状。此外,MSPI还能减少神经胶质细胞活化、大脑神经炎症反应和神经元凋亡,从而减轻抑郁样行为。
Description
技术领域
本发明涉及生物医药技术领域,具体涉及一种墨黑色素在制备治疗慢性溃疡性结肠炎及其伴随抑郁样行为的药物中的用途。
背景技术
炎症性肠病(IBD)的临床表现包括发作性腹痛、腹泻、血便、体重减轻。病理原因包括中性粒细胞和巨噬细胞透过肠屏障,细胞因子分泌异常、蛋白分解酶和自由基增加,导致炎症和溃疡。21世纪初,IBD已成为全球性疾病,在西方工业化国家中的发病率高于0.3%,在过去的20年,南美、中东及亚洲等发展中国家IBD的发病率和流行率陡升。根据流行病学预测,至2025年,中国的炎症性肠病患者人数将达到150万,这给医疗系统带来了严峻挑战。患病率和发病率逐年增加的炎症性肠病已成为一种全球性疾病,其病程长、治疗困难且反复发作,严重影响着患者的身体健康和生活质量。
此外,研究表明IBD患者除了肠道损伤等主要表现外,还常伴随着抑郁样行为,并且这种症状在溃疡性结肠炎疾病活动期更为明显。然而关于炎症性肠病的研究,目前大多集中于结肠组织病变,对抑郁样行为的研究并不深入。IBD的病理特征复杂,现有的常规治疗药物包括抗生素、免疫抑制剂等,无法完全治愈且复发率高,毒副作用大,容易对人体生理、心理造成严重损伤。
天然活性物质具有安全性高、副作用小、作用靶点多样等特点,已被广泛应用于慢性疾病的膳食补充剂和天然药物中。海洋头足类动物捕捞量逐年增加,但加工后墨囊等副产物被抛弃,不利于资源利用和生态环境发展。墨囊约占头足类体重的1.3%,其主要化学成分墨黑色素是最优质的天然真黑色素来源,因此开发墨黑色素对提高海产品加工废料利用率,促进海洋生物活性物质的开发具有重要意义。
墨鱼墨汁中黑色素(MSPI)是一种天然生物活性大分子,由5,6-二羟基吲哚和5,6-二羟基吲哚-2-羧酸分子组成。在早期的研究中,MSPI是一种球形颗粒,直径为90-140纳米,分子量为376,墨黑色素具有多种药理作用,包括抗氧化、抗炎、抗肥胖、抗衰老和可靠的生物相容性。然而,MSPI对慢性溃疡性结肠炎(UC)及其伴随的抑郁样行为的作用尚未见报道。
发明内容
本发明的目的在于克服现有技术存在的缺点,提供一种墨黑色素在制备治疗慢性溃疡性结肠炎及其伴随抑郁样行为的药物中的用途。
为了实现上述目的,本发明的技术方案是:墨黑色素在制备治疗慢性溃疡性结肠炎及其伴随抑郁样行为的药物中的用途。
进一步地;所述药物包含治疗上有效剂量的墨黑色素以及药学上可接受的辅料。
进一步地;所述药物的剂型为片剂。
进一步地;所述药物的剂型为胶囊剂。
进一步地;所述药物的剂型为注射剂。
本发明的有益效果:本发明首次发现墨黑色素具备治疗慢性溃疡性结肠炎及其伴随抑郁样行为的功效。MSPI可抑制LPS/TLR4/NLRP3/ASC/Caspase-1炎症信号通路,减轻氧化应激,恢复肠道屏障,从而改善UC症状。此外,MSPI还能减少神经胶质细胞活化、大脑神经炎症反应和神经元凋亡,从而减轻抑郁样行为。
附图说明
图1是慢性UC模型实验设计图;
图2是小鼠结肠长度对比图;
图3是小鼠疾病活动指数(DAI)对比图;
图4是小鼠结肠远端组织的H&E染色(×100)对比图;
图5是小鼠结肠组织AB染色(×100)图和结肠组织评分图;AB染色总分是染色强度评分与阳性细胞比例评分之和;染色强度评分:0分:无染色,没有检测到目标蛋白的表达;1分:弱染色,目标蛋白表达较弱,颜色淡而难以辨识;2分:中等染色,目标蛋白表达清晰可见,颜色中等;3分:强染色,目标蛋白表达强烈,颜色深且明显;阳性细胞比例评分:0分:0%,没有任何细胞呈阳性;1分:小于10%,少数细胞呈阳性;2分:10%至50%,部分细胞呈阳性;3分:大于50%,多数细胞呈阳性;
图6是小鼠结肠组织LPS和炎症因子IL-Iβ、IL-6、IFN-γ和TNF-α的表达图;
图7是小鼠结肠组织中Caspase-1、ASC、TLR4和NLRP3水平的Western印迹分析图及其含量柱状图;
图8是小鼠结肠组织MCP-I和F4/80免疫组化及评分图:A是小鼠结肠组织中MCP-1的免疫组化及评分图,B是小鼠结肠组织中F4/80的免疫组化及评分图;免疫组化得分=∑(pi×i)=(弱阳性区域百分比×1)+(中等阳性区域百分比×2)+(强阳性区域百分比×3);pi:阳性信号的像素面积;i:阳性水平;
图9是小鼠结肠组织ROS的免疫荧光染色(×100)及ROS水平图;
图10是小鼠结肠组织MDA和8-OHdG含量水平图;
图11是小鼠结肠中蛋白的(Caspase-3,Bax,Bcl-2,ZO-1和Occludin)的免疫组化和组织学评分图:A是Caspase-3,B是Bax,C是Bcl-2,D是ZO-1,E是Occludin;免疫组化得分=∑(pi×i)=(弱阳性区域百分比×1)+(中等阳性区域百分比×2)+(强阳性区域百分比×3);pi:阳性信号的像素面积;i:阳性水平;
图12是小鼠肠道菌群的α多样性分析:A是基于PCA和PCoA分数的小鼠肠道菌群聚类分析图,B是小鼠肠道微生物物种的维恩图;
图13是小鼠肠道菌群Chao1、Coverage、Shannoneven、Shannon和Simpson指数;
图14是小鼠肠道菌群在门水平上的物种组成;
图15是小鼠肠道菌群在科水平上的物种组成;
图16是小鼠肠道菌群在属水平上的物种组成;
图17是小鼠抑郁样行为(OFT、MBT、TST、FST和8臂迷宫行)的得分图;
图18是小鼠脑组织的H&E染色图和AB染色评分图:A是脑组织H&E染色(×100)图,B是脑组织AB染色(×200)和评分图;AB染色评分是染色强度评分与阳性细胞比例评分之和;染色强度评分:0分:无染色,没有检测到目标蛋白的表达;1分:弱染色,目标蛋白表达较弱,颜色淡而难以辨识;2分:中等染色,目标蛋白表达清晰可见,颜色中等;3分:强染色,目标蛋白表达强烈,颜色深且明显;阳性细胞比例评分:0分:0%,没有任何细胞呈阳性;1分:小于10%,少数细胞呈阳性;2分:10%至50%,部分细胞呈阳性;3分:大于50%,多数细胞呈阳性;
图19是小鼠脑部炎症水平和突触相关蛋白的表达:A是脑组织LPS含量柱状图,B是Western印迹图及脑组织中Caspase-1、ASC、TLR4和NLRP3的含量柱状图;
图20是小鼠脑部炎症水平和突触相关蛋白的表达,是脑组织中炎症因子IL-Iβ、IL-6、IFN-γ和TNF-α的含量水平图;
图21是小鼠脑组织Syn,DCX,BDNF和PSD-95的IHC染色和组织学评分图:A是Syn,B是DCX,C是BDNF,D是PSD-95;免疫组化得分=∑(pi×i)=(弱阳性区域百分比×1)+(中等阳性区域百分比×2)+(强阳性区域百分比×3);pi:阳性信号的像素面积;i:阳性水平;
图22是小鼠脑组织中氧化应激表达情况:A是脑组织ROS免疫荧光图,B是脑组织ROS、MDA和8-OHdG含量水平图,C是脑组织Bax的免疫组化染色图和组织学评分图,D是脑组织中Bcl-2的免疫组化染色图和组织学评分图;免疫组化得分=∑(pi×i)=(弱阳性区域百分比×1)+(中等阳性区域百分比×2)+(强阳性区域百分比×3);pi:阳性信号的像素面积;i:阳性水平;
图23是小鼠细胞凋亡和胶质细胞表达情况:A是脑组织Caspase-3的免疫组化染色图和组织学评分图,B是脑组织的TNUEL染色图和评分图,C是脑组织IBA-1的免疫组化染色图和组织学评分图,H是脑组织GFAP IHC的免疫组化染色图和组织学评分图;免疫组化得分=∑(pi×i)=(弱阳性区域百分比×1)+(中等阳性区域百分比×2)+(强阳性区域百分比×3);pi:阳性信号的像素面积;i:阳性水平;
图中:与空白组相比,#P<0.05,##P<0.01;与模型组相比,*P<0.05,**P<0.01。
具体实施方式
下面通过具体实施例对本发明技术方案进行详细说明,但是本发明的保护范围不局限于所述实施例。
本发明实施例中所用的未进行具体说明试验材料均为本领域常规的试验材料,均可通过商业渠道购买得到。
实施例1:
墨黑色素对慢性溃疡性结肠炎及其伴随抑郁样行为的治疗。
一、实验动物
雄性C57BL/6J小鼠(8周龄,20-25克)购自济南鹏越实验动物有限公司。实验前,小鼠在标准条件下(温度25±2℃,湿度55±5%)饲养7天,每笼四只,按照5g/只/天的用量喂食玉米饲料。适应性喂养7天后,将小鼠随机分为三组(8只/组),包括空白组、模型组和MSPI(150mg/kg/天)组。空白组和模型组连续七天只给予生理盐水灌胃,并按照5g/只/天的用量喂食玉米饲料,MSPI组(黑色素组)连续七天给予150mg/kg/天剂量的MSPI,并按照5g/只/天的用量喂食玉米饲料。然后在模型组和MSPI组中连续5天增加2mL的2%的DSS溶液灌胃,并在接下来的14天停止灌胃DSS溶液,只给予生理盐水灌胃。随后,再次增加2mL的2%的DSS溶液5天灌胃,并在接下来的连续14天中停止灌胃DSS溶液,只给予生理盐水灌胃。如此循环,建立了慢性UC模型(图1)。行为实验结束后,在无菌条件下收集小鼠粪便,然后用10%乙醚麻醉小鼠并进行颈椎脱臼。小鼠的结肠和脑组织在液氮中速冻后保存在-80℃下,或收集在4%多聚甲醛中,用于后续的生化分析。青岛科技大学动物伦理委员会批准了所有动物实验(编号:SYXK 2022-1009)。
二、试验方法
1、疾病活动指数(DAI)和抑郁样行为测试
使用疾病活动性指数评分来评估慢性结肠炎严重程度。DAI由体重变化、大便出血和大便粘稠度三种情况评分组成。体重下降有五个等级(0,无体重下降或体重增加;1,1%-10%;2,10%-15%;3,15%-20%;4,>20%),两个等级的大便稠度(0,正常;4,腹泻),两个等级的大便出血情况(0,正常;4,大便出血严重)。在DSS干预后,用综合三种情况评分计算DAI。即DAI=(体重指数+大便形状+出血情况)/3。随后,对小鼠进行了空旷场地试验(OFT)、弹珠掩埋试验(MBT)、八臂迷宫试验(8-Arm-Maze)、强迫游泳试验(FST)和尾悬吊试验(TST),以评估小鼠的抑郁行为。
(1)空旷场地试验
在旷场测试中,测试了小鼠旷野焦虑和探索活动。测试设备为一块50×50cm2高为40cm的正方形测试旷场。实验开始时捏住小鼠尾巴近端1/2~1/3处,轻轻放入旷场实验箱的中心网格中,适应1min后,记录后4min内小鼠的行为。在实验间隙中,用75%乙醇擦拭旷场,消除气味干扰。同时悬挂在其上的摄像头进行实时录像。试验结束后,记录小鼠总运动距离(总距离)和在中央运动的距离(中央距离),以及外围运动距离(外围距离)作为探索活动和抑郁的指标。
(2)弹珠掩埋实验
在弹珠掩埋实验期间,小鼠被放在无菌笼子里,笼子中铺满高度为5cm的玉米芯垫料,在其上均匀排布20个弹珠(排列成4排5列)。小鼠被允许自由探索30min,结束后拍照记录其掩埋弹珠的情况(每颗弹珠超过三分之二体积被垫料覆盖则被标记为掩埋)。小鼠探索完毕后使用75%乙醇擦拭弹珠和鼠笼并更换新垫料用于下一只小鼠实验。
(3)八臂迷宫试验
八臂径向迷宫对空间记忆的评估,八臂径向迷宫由8个等间距的臂组成,从一个八角形的中心平台向外辐射。实验过程为期5天,在实验开始之前,对小鼠进行限制饮食,保持在它们正常体重的85%。首先使小鼠习惯于径向臂迷宫两天,每天10min,然后将它们放在迷宫的中心,让每只小鼠自由活动。第三天,将诱饵放入每只手臂末端并让小鼠自由探索。第四天,随机选择四个臂在末端放入食物,八只手臂都走完后结束训练(如果整个身体都在手臂上,除了尾巴,就认为老鼠进入了迷宫的一只手臂)或10min后结束训练试验。第五天,进行与第四天相同的实际试验,观察小鼠在实验中是否记得放入食物的臂。在每次试验之间用75%的乙醇将迷宫擦拭干净,以防止出现任何气味线索。使用摄像头拍摄记录整个实验中的小鼠活动行为。试验结束后通过分析其工作记忆错误和参考记忆错误以评估短期和长期记忆错误情况。只有第一次进入诱饵手臂的手臂才被记录为正确的选择,重新进入先前进入过的手臂被视为工作记忆错误,进入非诱饵手臂被视为参考记忆错误。
(4)强迫游泳实验
实验过程中小鼠被放置在一个直径17.5cm,高度20cm的透明圆柱体中,圆柱体中水高10cm,保持水温维持在25℃,避免小鼠体温过低。并对小鼠进行6min的录像。在试验的最后4min内测量小鼠保持不动的总时间。不动被定义为小鼠处于静止姿势的情况,即除了保持头部露出水面所必需的动作之外没有动作,使用秒表手动评分。测试结束时,将老鼠在温暖的笼子里干燥15min后放回笼子。每次实验间换成洁净水。
(5)尾悬吊试验
将小鼠尾巴固定在横杆上(距尾尖约1cm),从尾部悬吊,小鼠的鼻尖与地面之间的距离约为20cm。小鼠保持悬挂状态6min并拍摄记录,开始时,小鼠会表现出积极活动状态以适应环境,一段时间后会出现间歇性静止行为,代表此时小鼠处于绝望状态。实验结束后,观察者对每个个体在6min的最后4min内不动的时间进行评分。
2、苏木精-伊红(H&E)和阿利新蓝(AB)染色
将甲醛固定的结肠和脑组织分别垂直嵌入石蜡中,切成5μm的切片,脱蜡并水化,冻存备用。分别对切片进行H&E和AB染色。用光学显微镜观察组织,并通过确定细胞损伤程度和炎症细胞浸润程度进行评分。
3、尼氏染色
将上述冻存切片用4%PFA固定液固定20min,然后用蒸馏水冲洗,使用Nissl染色法染色5min,然后用蒸馏水冲洗两次,再用70%乙醇冲洗。最后,使用荧光显微镜观察海马图像,并使用Image Pro-Plus软件对海马齿状回区域清晰完整、核周围均匀分布有nissl小泡的神经元细胞进行计数。
4、细胞凋亡试验(TUNEL)
使用细胞凋亡检测试剂盒(Roche,Indianapolis,IN,USA)检测上述冻存切片中的细胞凋亡。使用显微镜拍照(BX53,Olympus,Tokyo,Japan)。根据五个不同视野中阳性细胞的平均数量计算阳性细胞总数的百分比。凋亡指数=凋亡细胞数/计数细胞总数×100。
5、Westernblot(WB)检测
用预冷的冷冻RIPA裂解缓冲液分别裂解结肠和脑组织,并按照生产商的说明提取总蛋白。12%SDS-PAGE分离后,将蛋白裂解液转移到PVDF膜上。在4℃下用特异性一抗(1/1000)孵育膜一整夜,然后用适当的二抗孵育膜。使用ECL将图像显示在凝胶系统上。
6、酶联免疫吸附试验(ELISA)
新鲜切除的结肠和脑组织分别用磷酸二氢钾缓冲液(pH 6.8)匀浆,4℃10000g离心15min,取上清液。用ELISA试剂盒检测结肠和脑组织中TNF-α、IL-6、IFN-γ、IL-1β、MDA和8-OHdG的含量,用BCA蛋白检测试剂盒检测蛋白质含量。在450nm波长下测量吸光度。
7、免疫组化(IHC)测定
在4℃下使用4%多聚甲醛浸泡固定新鲜切除的结肠和脑组织,闭塞孵育一抗。在用PBS洗涤三次后,用适当的二抗显影结肠和脑组织,在光学显微镜下拍摄。用ImageJ软件测量细胞数。对于免疫荧光,采用双抗原免疫荧光检测组织中ROS的表达水平,并通过使用荧光显微镜检测荧光素进行分析。使用ImageJ软件测量阈值信号强度范围内选定的区域。H-Score:H-SCORE=∑(pi×i)=(弱阳性区域百分比×1)+(中等阳性区域百分比×2)+(强阳性区域百分比×3)。pi:阳性信号的像素面积;i:阳性水平。
8、粪便微生物菌群的16S rRNA分析
测序在Majorbio平台上进行。用FastDNA spin试剂盒从每个样本中获得总DNA,然后收集PCR扩增的结果进行荧光定量。定量使用微孔板阅读器(Flx800,BioTek,美国)进行。根据荧光定量的结果和测序量的需要对样品进行比例分配16S rRNA基因的v3~v4高变异区在PE150模式下在Illumina测序仪上进行扩增和测序。
三、实验结果
1、MSPI可改善DSS引起的慢性结肠炎症状
DSS干预后,小鼠表现出消瘦、腹泻和粪便带血等症状。与空白组相比,模型组小鼠表现出明显的UC症状,如结肠缩短(图2)和DAI评分明显升高(图3)。MSPI的干预明显缓解了小鼠的UC症状,使肠壁肿胀减轻,肠道长度恢复正常。H&E染色(图4)显示,空白组小鼠的结肠粘膜未受损伤,绒毛清晰可见,隐窝完整,腺体排列整齐,无炎症细胞浸润或溃疡。AB染色(图5)显示,模型组结肠组织中的杯状细胞显著减少,导致粘液层严重受损,粘液所剩无几。与模型组相比,MSPI干预疗法有助于恢复粘液层的完整性(P<0.01)并维持物理保护屏障。
2、MSPI可减轻炎症反应和肠道巨噬细胞浸润
脂多糖(LPS)可刺激免疫系统细胞,诱发强烈的炎症反应。采用LPS试剂盒提取小鼠组织中的LPS,获得提取液,使用酶标检测仪在450nm处测定吸光度。从图6可以看出,模型组小鼠结肠组织中的LPS含量明显高于空白组,而MSPI组则明显低于模型组(P<0.01)。WB检测了小鼠体内TLR4、NLRP3、ASC和Caspase-1炎性体的表达(图7),ACTIN单克隆抗体(ACTIN)为标准参照物。结果表明,与空白组相比模型组小鼠结肠中上述蛋白的表达均明显增加(P<0.01)。此外,免疫组化结果显示(图8),模型组小鼠结肠组织中单核细胞趋化蛋白-1(MCP-1)和巨噬细胞标记物F4/80的高表达明显高于空白组(P<0.01)。相反,MSPI干预后,其在结肠中的高表达明显逆转。
3、MSPI可减轻UC小鼠的氧化应激和细胞凋亡,并增强肠道屏障
氧化应激是UC的一个典型特征。如图9所示,与空白组相比,模型组小鼠的活性氧(ROS)水平显著升高,而MSPI的干预对ROS有显著的抑制作用(P<0.01)。ELISA结果显示,与空白组相比,模型组的MDA(丙二醛)和8-OHdG水平明显升高,而MSPI干预则明显降低了氧化应激的表达(图10)。而且,模型组Caspase-3和Bax的表达均明显高于空白组,而抑制细胞凋亡的蛋白Bcl-2的表达则受到抑制(图11中A-C)。MSPI逆转了上述蛋白的表达。
细胞凋亡会增加肠道通透性并加剧肠粘膜屏障功能障碍。为了进一步确定MSPI的干预是否能改善肠道屏障的完整性,我们使用IHC染色法检测了小鼠结肠中紧密连接(TJ)蛋白(Ocludin、ZO-1)的表达水平(图11中D-E)。模型组TJ蛋白的表达水平明显低于空白组(P<0.01),而使用MSPI治疗后,上述TJ蛋白的表达水平明显恢复(P<0.01)。
4、肠道微生物群中的MSPI调节
肠道微生物群的破坏会导致炎症和肠道环境的异常。从图12可以看出,模型组的肠道微生物群组成发生了显著变化。采用Chao1、Coverage、Shannoneven、Shannon和Simpson指数评估菌群的α-多样性(图13),与模型组相比,口服MSPI可明显增加微生物多样性和相对丰度,与空白组相比,MSPI组微生物多样性和相对丰度明显降低(P<0.01),MSPI组更接近空白组。利用主成分分析(PCA)和主坐标分析(PCoA)对不同组的高通量测序结果进行了肠道微生物群β多样性分析(图12中A),结果显示空白组和MSPI组聚集在一起,与模型组明显分开。
随后,通过分析各类微生物在特定分类水平上的相对丰度发现(图14,图15,图16),在门级水平上,类杆菌和放线菌在模型小鼠中的相对丰度分别下降了22%和4.6%,而固着菌和蠕形微生物在模型小鼠中的相对丰度分别增加了20%和5.6%,MSPI的干预扭转了这一趋势。此外,健康小鼠体内的益生菌群主要是穆氏菌属、杜博氏菌属、双歧杆菌属和乳酸杆菌属。但通过MSPI的干预,它们的丰度得到了明显恢复,从而使肠道微生物群的构成趋于正常。
5、MSPI可明显缓解抑郁样行为
研究结果表明,在OFT实验中,模型组小鼠的平均中心活动距离显著减少,外周探索行为增加(图17)。MSPI干预能有效增加小鼠的中心活动距离。在MBT中,模型组小鼠能埋藏76.7±3.6%的弹珠,而MSPI组小鼠能埋藏9.3±1.2%的弹珠,这显著减少了小鼠的刻板重复行为。在进行TST时,模型组小鼠保持静止的时间明显更长(P<0.01),这代表了更长的绝望期。TST的结果与FST的结果相当。静止时间的减少和自发活动时间的增加表明,MSPI干预对抑郁小鼠有益。最后,8臂迷宫的结果表明,模型小鼠的工作记忆错误和参考记忆错误显著增加,而MSPI干预则显著降低了错误频率。
6、MSPI可减轻神经元损伤
H&E染色结果(图18中A)表明,模型组小鼠脑组织细胞排列不规则,正常细胞数量减少,细胞核缩小,炎性细胞浸润增多,海马出现轻度水肿、中性粒细胞固定等神经元变性症状。MSPI的干预明显减少了浸润细胞的数量,恢复了细胞形态,并改善了小鼠海马的神经元退化症状。Nissl染色也观察到了类似的结果(图18中B)。空白组小鼠的神经元细胞结构完整,形态规则,细胞核明显,胞浆中有丰富的尼氏体,锥体神经元明显。MSPI组的神经元细胞形态改善,细胞水肿减轻,Nissl体数量增加,形态和数量均有显著改善。
7、MSPI调节小鼠大脑中的炎症通路并减少炎症细胞因子的表达
抗抑郁治疗的机制包括降低大脑中神经炎因子的水平。结果显示(图19),慢性UC显著增加了小鼠大脑中的炎症蛋白TLR4、NLRP3、ASC和Caspase-1的水平,而MSPI的干预则显著降低了它们的水平。此外,模型小鼠大脑中促炎细胞因子的表达明显升高,而MSPI的干预则明显抑制了促炎细胞因子水平的升高(图20)。
8、MSPI逆转慢性UC引起的突触蛋白损伤
大脑中的神经元通过突触连接起来。结果显示突触后密度95(PSD-95)和突触素(Syn)在模型组明显下调(图21),而在MSPI组则恢复。此外,与空白组相比,模型组的双皮质素(DCX)和脑源性神经营养因子(BDNF)减少(P<0.01)。因此,我们假设MSPI可以通过增加突触相关蛋白的表达来改善认知功能障碍和抑郁样行为。
9、MSPI可减轻小鼠大脑的氧化应激反应
抑郁样行为往往伴随着大脑氧化应激的增加。数据显示(图22中A-B),模型组脑组织中ROS的表达水平明显高于空白组(P<0.01),MSPI干预后明显低于模型组(P<0.01)。ELISA检测表明,MSPI组脑组织中8-OHdG和MDA的表达量明显低于模型组(P<0.01)。
10、MSPI调节慢性UC小鼠脑组织的细胞凋亡
通过评估UC诱导的脑细胞凋亡,发现模型组中Bcl-2的表达量减少,而Caspase-3和Bax的表达量显著增加。MSPI的干预明显逆转了这一变化(图22中C-D,图23中A)。然后用TUNEL染色法测量了小鼠大脑中凋亡细胞的浓度(图23中B),在模型组小鼠中观察到的抑郁症状伴随着脑细胞凋亡的显著增加。MSPI治疗将凋亡的增加降至接近空白组的水平。
11、MSPI可降低小鼠脑内小胶质细胞和星形胶质细胞的活化程度
小胶质细胞和星形胶质细胞的慢性激活会导致促炎细胞因子的持续产生,从而引发神经退行性疾病。IBA-1和GFAP的免疫组化结果显示,与空白组相比,模型组的小胶质细胞和星形胶质细胞表现为体节增大、分叉突起回缩、突起变粗、突起数量增加(图23)。除形态学变化外,定量分析还发现,模型组活化的星形胶质细胞和小胶质细胞数量明显高于空白组,而MSPI组活化的小胶质细胞和星形胶质细胞数量明显低于模型组(P<0.01)。这表明MSPI的干预可以通过控制神经胶质细胞的活化来调节神经炎症。
四、结果讨论
随着IBD发病率和患病率的增加,其合并症抑郁症和其他中枢神经系统疾病也日益受到关注。DSS诱导的UC小鼠模型与人类UC表现相似,是研究UC发病机制和药物治疗的实用方法。粘液层在肠道稳态中起着关键作用,杯状细胞分泌的保护性粘蛋白和其他蛋白质对屏障功能的完整性和抑制微生物群驱动的肠道炎症至关重要。它们的缺乏会引发炎症。对小鼠结肠的病理分析证实,在DSS诱导的UC后,产生粘液的上皮细胞严重丧失。MSPI可改善结肠的炎症损伤,帮助恢复粘液层的完整性并维持物理保护屏障。
LPS是大多数革兰氏阴性细菌细胞壁的主要成分,可刺激免疫系统细胞并诱发强烈的炎症反应。肠道中增加的促炎因子会引发炎症级联反应,导致结肠组织损伤和慢性炎症。巨噬细胞浸润是UC的组织学特征之一,并与炎症一起持续存在。肠道巨噬细胞的作用及其对肠道炎症发展的影响受多种因素调控,例如MCP-1的产生会导致巨噬细胞进一步聚集并加速结肠组织的炎症,而细胞表面糖蛋白F4/80的表达仅限于巨噬细胞系,是巨噬细胞的标记物。我们的研究表明,MSPI干预显著逆转了DSS诱导的肠道LPS和炎症因子的升高,起到了减轻肠道炎症的作用。
氧化应激通常被定义为抗氧化系统与有毒ROS之间的不平衡所造成的损伤。MDA是ROS诱导的细胞膜脂质过氧化的最终产物,而8-OHdG则是DNA损伤和氧化应激的标志物。此外,氧化应激会引发上皮细胞凋亡。Bcl-2是第一个被发现能防止细胞凋亡的调节蛋白。Bcl-2与Bax的比例降低会通过激活caspase-3增强线粒体凋亡信号,从而诱导细胞凋亡,增加肠道通透性,加剧肠粘膜屏障功能障碍,这是UC的一个主要致病因素。肠上皮利用TJ蛋白维持肠屏障的完整性,而肠屏障的破坏主要是由炎症因子介导的。肠上皮细胞凋亡会影响TJ蛋白。这些蛋白质主要由Ocludin和ZO-1组成,可阻止细菌粘附和细菌向宿主组织细胞扩。与空白组相比,模型组细胞凋亡相关蛋白明显表达,抑制细胞凋亡蛋白Bcl-2的表达受到抑制,TJ蛋白的表达水平明显低于空白组。MSPI的干预逆转了上述变化,表明它具有降低氧化应激、减少细胞凋亡和修复肠道屏障的能力。
当肠道粘膜屏障受损时,粘膜通透性增加,肠道微生物群产生的LPS等小分子物质更容易通过肠腔进入血液,穿过血脑屏障,刺激脑部炎症通路,促进炎性细胞因子的释放,导致神经炎症和退行性病变,从而加重认知障。抗抑郁治疗的机制之一可能是降低大脑中的LPS水平。我们的研究结果表明,慢性UC会显著增加脑内LPS水平,激活LPS/TLR4/NLRP3/ASC/Caspase-1炎症通路,加速模型组炎症因子的表达,而MSPI可通过抑制炎症通路来减少炎症因子。
大脑中的氧化应激会增加神经元凋亡和DNA损伤,被认为是抑郁症的致病因素之一。处于氧化应激下的生物体会导致蛋白酶分泌增加,并产生大量氧化化合物。同时,大量与炎症相关的转录因子在氧化应激下被激活,启动炎症过程并增加促炎细胞因子分泌。这与我们研究结果一致,即慢性UC会增加体内氧化应激水平并导致脑组织氧化损伤,而与模型组相比,MSPI可减少氧化应激引起的组织损伤,并对抑郁样行为的调节产生积极影响。
过度的细胞凋亡是抑郁样行为的重要诱因。实验结果证实,MSPI对炎症诱导的细胞凋亡和抑郁样行为具有神经保护能力,突触相关蛋白参与突触发生和神经递质释放的调控,并在突触可塑性和记忆形成中发挥关键作用。PSD-95和SYN是两种重要的支架蛋白,在突触可塑性和突触增强中具有关键功能。与空白组相比,模型组中的这两种蛋白明显下调。DCX是一种微管蛋白,对神经元在发育过程中的正常迁移至关重要,已被广泛用作有丝分裂后未成熟神经元的标志物和判断脑损伤的指标。我们的实验结果表明,模型小鼠的海马出现了神经元病变的迹象,与空白组相比,突触相关蛋白的水平下调。此外,一些与突触可塑性相关的关键调控蛋白,如BDNF,在模型组中也明显降低。因此,我们的研究结果表明,MSPI可以通过恢复突触相关蛋白的表达来改善认知功能障碍和抑郁样行为。
神经胶质细胞是大脑常驻的免疫细胞,通常会对损伤、压力和感染等病理刺激做出反应,学习和记忆行为也会受到胶质细胞激活的影响。星形胶质细胞和小胶质细胞是主要负责免疫调节和炎症反应的脑细胞。活化的小胶质细胞可通过吞噬作用破坏神经元,或产生神经毒性细胞因子和趋化因子,导致神经功能紊乱和细胞凋亡,从而促进神经元死亡或抑制神经元功能。IBA-1是小胶质细胞膜肌动蛋白交联的关键参与者。参与,其表达随小胶质细胞活化而增加,是小胶质细胞活化的标志物。星形胶质细胞位于神经元和毛细血管之间,是正常脑神经系统血脑屏障的重要组成部分。脑损伤后,星形胶质细胞被激活,表现出神经毒性效应,抑制神经元细胞生长和轴突再生。GFAP是星形胶质细胞活化的标志物,免疫染色后可观察到星形胶质细胞的形态变化。我们的结果表明,与模型组相比,MSPI干预可通过抑制神经胶质细胞的活化来调节神经免疫反应。
总之,本研究为MSPI治疗慢性UC及其伴随的抑郁样行为的潜在机制提供了有力证据。研究结果表明,MSPI可抑制LPS/TLR4/NLRP3/ASC/Caspase-1炎症信号通路,减轻氧化应激,恢复肠道屏障,从而改善UC症状。此外,MSPI还能减少神经胶质细胞活化、大脑神经炎症反应和神经元凋亡,从而减轻抑郁样行为。这表明MSPI可作为一种药物成分,通过关键的微生物群-肠-脑轴途径治疗慢性UC及其伴随的抑郁样行为。
以上所述的实施例只是本发明较佳的方案,并非对本发明作任何形式上的限制,在不超出权利要求所记载的技术方案的前提下还有其它的变体及改型。
Claims (5)
1.墨鱼墨汁中黑色素在制备治疗慢性溃疡性结肠炎伴随的抑郁样行为的药物中的用途。
2.根据权利要求1所述的用途,其特征在于:所述药物包含墨鱼墨汁中黑色素以及药学上可接受的辅料。
3.根据权利要求1所述的用途,其特征在于:所述药物的剂型为片剂。
4.根据权利要求1所述的用途,其特征在于:所述药物的剂型为胶囊剂。
5.根据权利要求1所述的用途,其特征在于:所述药物的剂型为注射剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410496410.3A CN118512481B (zh) | 2024-04-24 | 2024-04-24 | 墨黑色素在制备治疗慢性溃疡性结肠炎及其伴随抑郁样行为的药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410496410.3A CN118512481B (zh) | 2024-04-24 | 2024-04-24 | 墨黑色素在制备治疗慢性溃疡性结肠炎及其伴随抑郁样行为的药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN118512481A CN118512481A (zh) | 2024-08-20 |
CN118512481B true CN118512481B (zh) | 2025-01-07 |
Family
ID=92276335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410496410.3A Active CN118512481B (zh) | 2024-04-24 | 2024-04-24 | 墨黑色素在制备治疗慢性溃疡性结肠炎及其伴随抑郁样行为的药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118512481B (zh) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103007145B (zh) * | 2012-12-28 | 2014-10-15 | 青岛华仁技术孵化器有限公司 | 一种治疗小儿轮状病毒肠炎的中药组合物及其制备方法 |
CN106266291A (zh) * | 2016-08-31 | 2017-01-04 | 高怀秀 | 一种治疗溃疡性结肠炎的中西药复方制剂及制备方法 |
CN113855709B (zh) * | 2021-10-19 | 2024-02-06 | 温州医科大学附属第一医院 | 一种包含普雷沃氏菌的产品在治疗和预防抑郁症中的应用 |
CN116211992B (zh) * | 2023-03-22 | 2023-11-21 | 重庆市中医院 | 一种用于治疗溃疡性结肠炎诱发抑郁样行为的中药组合物 |
-
2024
- 2024-04-24 CN CN202410496410.3A patent/CN118512481B/zh active Active
Non-Patent Citations (1)
Title |
---|
墨鱼黑色素提取、表征及其对急性肠炎的影响研究;张景禹;《中国优秀硕士学位论文全文数据库 农业科技辑》;20210115(第01期);D052-181 * |
Also Published As
Publication number | Publication date |
---|---|
CN118512481A (zh) | 2024-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xu et al. | Caspase-1 inhibitor exerts brain-protective effects against sepsis-associated encephalopathy and cognitive impairments in a mouse model of sepsis | |
Sun et al. | Microbiota-derived metabolite Indoles induced aryl hydrocarbon receptor activation and inhibited neuroinflammation in APP/PS1 mice | |
Xu et al. | Yeast β-glucan alleviates cognitive deficit by regulating gut microbiota and metabolites in Aβ1–42-induced AD-like mice | |
Huang et al. | The ketone body metabolite β‐hydroxybutyrate induces an antidepression‐associated ramification of microglia via HDACs inhibition‐triggered Akt‐small RhoGTPase activation | |
Welcome | Gut microbiota disorder, gut epithelial and blood–brain barrier dysfunctions in etiopathogenesis of dementia: molecular mechanisms and signaling pathways | |
US20180303743A1 (en) | Novel recombinant high-stability superoxide dismutase and application thereof | |
US20160220602A1 (en) | Use of chinese medicine preparation in preparing drug for preventing and/or treating crohn's disease | |
CN113855709B (zh) | 一种包含普雷沃氏菌的产品在治疗和预防抑郁症中的应用 | |
Song et al. | Baicalein ameliorates cognitive impairment of vascular dementia rats via suppressing neuroinflammation and regulating intestinal microbiota | |
Zhao et al. | Changes in intestinal barrier protein expression and intestinal flora in a rat model of visceral hypersensitivity | |
Zhou et al. | Zizyphus jujuba cv. Muzao polysaccharides enhance intestinal barrier function and improve the survival of septic mice | |
Wu et al. | Citrus Alkaline Extract Delayed the Progression of Pulmonary Fibrosis by Inhibiting p38/NF‐κB Signaling Pathway‐Induced Cell Apoptosis | |
JP2021530494A (ja) | 胃腸障害の治療における徐放性5−ヒドロキシトリプトファンの使用 | |
CN114869869B (zh) | Eugenol在预防和/或治疗骨关节炎中的应用 | |
CN118512481B (zh) | 墨黑色素在制备治疗慢性溃疡性结肠炎及其伴随抑郁样行为的药物中的用途 | |
JP2023065364A (ja) | 脳内の炎症の抑制又は軽減剤 | |
Gao et al. | Acteoside ameliorates learning and memory impairment in APP/PS1 transgenic mice by increasing Aβ degradation and inhibiting tau hyperphosphorylation | |
CN112933117B (zh) | 一种预防和/或治疗帕金森病的药物及其应用 | |
Jiraungkoorskul et al. | Eurytrema pancreaticum: the in vitro effect of praziquantel and triclabendazole on the adult fluke | |
Zou et al. | Asiatic acid and andrographolide reduce hippocampal injury through suppressing neuroinflammation caused by Salmonella typhimurium infection | |
Lin et al. | [Retracted] The Conditioned Medium of Lactobacillus rhamnoides GG Regulates Microglia/Macrophage Polarization and Improves Functional Recovery after Spinal Cord Injury in Rats | |
Long et al. | Minocycline ameliorated LPS-induced learning and memory impairment by inhibiting microglia and astrocytes activation in the hippocampus | |
WO2020082941A1 (zh) | 吉非罗齐及其衍生物用于治疗和/或预防神经退行性疾病的用途 | |
JP2022552510A (ja) | 胃腸の健康組成物 | |
Rötting et al. | Effects of ischemia and reperfusion on eosinophilic accumulation and distribution in mucosa of equine jejunum and colon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |